Abstract
Although a great body of evidence is available on the immunosuppressive strategies employed by tumors in order to grow, cancer patients are not considered immunosuppressed individuals. Chemotherapy used in different cancer treatments frequently leads to leucopenia and affects immune responses. Tumors of the immune system can also cause immune alterations, due to their very nature. However, in the absence of preventive routine exams, patients can bear tumors for rather long periods of time without any specific indication, not being particularly prone to contracting infectious diseases compared to cancer free individuals. In this review, we analyze the existing data on the effects of tumors on the immune system of cancer patients. An interesting pattern emerges, suggesting that immunosuppression exerted by tumors is mainly local, rather than systemic. However, some alterations in DCs of cancer patients have been recently described, indicating the interactions between tumor and immune cells may be more complex than previously imagined. This has important implications of the design of anti-tumor therapies as well as in patient quality of life.
Keywords: cancer, immunity, inflammation, immunotherapy, immunosuppressive, chemotherapy, leucopenia, anti-tumor therapies, cytokines, NKG2D
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: The Immune System of Cancer Patients
Volume: 10 Issue: 4
Author(s): Carolina Torronteguy and Ana Paula Souza e Cristina Bonorino
Affiliation:
Keywords: cancer, immunity, inflammation, immunotherapy, immunosuppressive, chemotherapy, leucopenia, anti-tumor therapies, cytokines, NKG2D
Abstract: Although a great body of evidence is available on the immunosuppressive strategies employed by tumors in order to grow, cancer patients are not considered immunosuppressed individuals. Chemotherapy used in different cancer treatments frequently leads to leucopenia and affects immune responses. Tumors of the immune system can also cause immune alterations, due to their very nature. However, in the absence of preventive routine exams, patients can bear tumors for rather long periods of time without any specific indication, not being particularly prone to contracting infectious diseases compared to cancer free individuals. In this review, we analyze the existing data on the effects of tumors on the immune system of cancer patients. An interesting pattern emerges, suggesting that immunosuppression exerted by tumors is mainly local, rather than systemic. However, some alterations in DCs of cancer patients have been recently described, indicating the interactions between tumor and immune cells may be more complex than previously imagined. This has important implications of the design of anti-tumor therapies as well as in patient quality of life.
Export Options
About this article
Cite this article as:
Torronteguy Carolina and Paula Souza e Cristina Bonorino Ana, The Immune System of Cancer Patients, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (4) . https://dx.doi.org/10.2174/187152311797928126
DOI https://dx.doi.org/10.2174/187152311797928126 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Recent Advances in PUVA Photochemotherapy and PDT for the Treatment of Cancer
Current Pharmaceutical Design Synthesis and Clinical Development of Palbociclib: An Overview
Medicinal Chemistry 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Anti-Cancer Agents in Medicinal Chemistry Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism Emergence of Functionalized Nanomedicines in Cancer Chemotherapy: Recent Advancements, Current Challenges and Toxicity Considerations
Recent Patents on Nanomedicine Clinical Significance of Breast Cancer Resistance Protein/ABCG2 in the Management of Malignancy
Clinical Cancer Drugs A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Extracellular Matrix and Aberrant Signaling in Lung Carcinoma: Role of Fibronectin in the Control of Human Lung Carcinoma Cell Growth,Apoptosis and Resistance to Therapy
Current Signal Transduction Therapy Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Behavioral Decision Research Intervention Reduces Risky Sexual Behavior
Current HIV Research Nanoparticles Mediated Target-specific Drug Delivery in Prostate Cancer: An In-depth Review
Current Medicinal Chemistry Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine